Children's Cancer Research Fund

Because of you, researchers at the University of Minnesota have opened a new clinical trial to treat brain tumors – and they’ve begun treating their first patient.

University of Minnesota researchers Dr. Michael Olin and Dr. Christopher Moertel developed the treatment with the goal of “turning off” a protein, called CD200, that shields glioblastoma tumors from a person’s immune system. Once that shield has been turned off, a vaccine to boost the patient’s immune system is able to attack the tumor directly. Right now, the inhibitor drug is being tested in adults, and once researchers have determined the best dose, they can use the results of the adult trial to begin a clinical trial for children.

Donate

By donating to Children’s Cancer Research Fund, you’ve been a part of this groundbreaking research project. You are part of the reason Dr. Olin and Dr. Moertel discovered this CD200 protein, and you funded their work developing the drug that will turn this protein off and open the door to a cure.

“CCRF's support for our early experiments got this going to the point of an FDA-approved clinical trial,” Dr. Moertel said. “Now, CCRF support for the clinical trial itself brings this seven-year project to its climax.”

You’ve helped these researchers take an idea all the way to a clinical trial in just a few years. Families who receive a glioblastoma diagnosis will have more hope today because of the progress you’ve made possible with your donation.

This would not have happened without your support, and we are truly grateful for your dedication to finding better treatments for children with cancer.

You can continue supporting research that will help more children with cancer become survivors. Click here to donate and give researchers the funds they need to move potentially groundbreaking work forward.

Make a Donation